Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Hemodynamic Effects of Pulmonary Arterial Hypertension-Specific Therapy in Patients With Heart Failure With Preserved Ejection Fraction and With Comined Post- and Precapillay Pulmonary Hypertension.

Huis In't Veld AE, Oosterveer FPT, De Man FS, Marcus JT, Nossent EJ, Boonstra A, Van Rossum ACB, Vonk Noordegraaf A, Bogaard HJ, Handoko ML.

J Card Fail. 2019 Aug 5. pii: S1071-9164(18)31294-6. doi: 10.1016/j.cardfail.2019.07.547. [Epub ahead of print]

PMID:
31394199
2.

The right treatment for the right ventricle.

Groeneveldt JA, de Man FS, Westerhof BE.

Curr Opin Pulm Med. 2019 Sep;25(5):410-417. doi: 10.1097/MCP.0000000000000610.

3.

Vena cava backflow and right ventricular stiffness in pulmonary arterial hypertension.

Marcus JT, Westerhof BE, Groeneveldt JA, Bogaard HJ, de Man FS, Vonk Noordegraaf A.

Eur Respir J. 2019 Jul 18. pii: 1900625. doi: 10.1183/13993003.00625-2019. [Epub ahead of print]

PMID:
31320456
4.

The right treatment for the right ventricle.

Groeneveldt JA, de Man FS, Westerhof BE.

Curr Opin Pulm Med. 2019 Jul 22. doi: 10.1097/MCP.0000000000000610. [Epub ahead of print]

PMID:
31313743
5.

Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure.

Andersen S, Axelsen JB, Ringgaard S, Nyengaard JR, Hyldebrandt JA, Bogaard HJ, de Man FS, Nielsen-Kudsk JE, Andersen A.

Int J Cardiol. 2019 Oct 15;293:203-210. doi: 10.1016/j.ijcard.2019.06.065. Epub 2019 Jun 29.

PMID:
31307846
6.

Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling.

Kurakula K, Sun XQ, Happé C, da Silva Goncalves Bos D, Szulcek R, Schalij I, Wiesmeijer KC, Lodder K, Tu L, Guignabert C, de Vries CJM, de Man FS, Vonk Noordegraaf A, Ten Dijke P, Goumans MJ, Bogaard HJ.

Eur Respir J. 2019 Sep 29;54(3). pii: 1802400. doi: 10.1183/13993003.02400-2018. Print 2019 Sep.

PMID:
31273046
7.

Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients.

de Man FM, van Eerden RAG, Oomen-de Hoop E, Veraart JN, van Doorn N, van Doorn L, van der Gaast A, Mathijssen RHJ.

Cancers (Basel). 2019 Jun 13;11(6). pii: E826. doi: 10.3390/cancers11060826.

8.

Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.

Buiten RA, Ploumen EH, Zocca P, Doggen CJM, van der Heijden LC, Kok MM, Danse PW, Schotborgh CE, Scholte M, de Man FHAF, Linssen GCM, von Birgelen C.

JAMA Cardiol. 2019 Jul 1;4(7):659-669. doi: 10.1001/jamacardio.2019.1776.

PMID:
31111862
9.

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine.

de Man FM, Veerman GDM, Oomen-de Hoop E, Deenen MJ, Meulendijks D, Mandigers CMPW, Soesan M, Schellens JHM, van Meerten E, van Gelder T, Mathijssen RHJ.

Ther Adv Med Oncol. 2019 Apr 15;11:1758835919838964. doi: 10.1177/1758835919838964. eCollection 2019.

10.

Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone.

Andersen S, Birkmose Axelsen J, Ringgaard S, Randel Nyengaard J, Holm Nielsen S, Genovese F, Asser Karsdal M, Adler Hyldebrandt J, Brandt Sørensen C, de Man FS, Jan Bogaard H, Erik Nielsen-Kudsk J, Andersen A.

Pulm Circ. 2019 Apr-Jun;9(2):2045894019848659. doi: 10.1177/2045894019848659.

11.

The unknown pathophysiological relevance of right ventricular hypertrophy in pulmonary arterial hypertension.

de Man FS, Handoko ML, Vonk-Noordegraaf A.

Eur Respir J. 2019 Apr 4;53(4). pii: 1900255. doi: 10.1183/13993003.00255-2019. Print 2019 Apr. No abstract available.

PMID:
30948507
12.

Highlights from the ERS International Congress 2018: Assembly 13 - Pulmonary Vascular Diseases.

Ramjug S, Adão R, Lewis R, Coste F, de Man F, Jimenez D, Sitbon O, Delcroix M, Vonk-Noordegraaf A.

ERJ Open Res. 2019 Mar 18;5(1). pii: 00202-2018. doi: 10.1183/23120541.00202-2018. eCollection 2019 Feb.

13.

Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer.

Toxopeus ELA, de Man FM, Krak N, Biermann K, Nieuweboer AJM, Friberg LE, Oomen-de Hoop E, van Lanschot JJB, Shapiro J, Wijnhoven BPL, Mathijssen RHJ.

Cancers (Basel). 2019 Feb 1;11(2). pii: E173. doi: 10.3390/cancers11020173.

14.

Right Ventricular Fibrosis.

Andersen S, Nielsen-Kudsk JE, Vonk Noordegraaf A, de Man FS.

Circulation. 2019 Jan 8;139(2):269-285. doi: 10.1161/CIRCULATIONAHA.118.035326.

PMID:
30615500
15.

ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension.

Grünig E, Eichstaedt C, Barberà JA, Benjamin N, Blanco I, Bossone E, Cittadini A, Coghlan G, Corris P, D'Alto M, D'Andrea A, Delcroix M, de Man F, Gaine S, Ghio S, Gibbs S, Gumbiene L, Howard LS, Johnson M, Jurevičienė E, Kiely DG, Kovacs G, MacKenzie A, Marra AM, McCaffrey N, McCaughey P, Naeije R, Olschewski H, Pepke-Zaba J, Reis A, Santos M, Saxer S, Tulloh RM, Ulrich S, Vonk Noordegraaf A, Peacock AJ.

Eur Respir J. 2019 Feb 28;53(2). pii: 1800332. doi: 10.1183/13993003.00332-2018. Print 2019 Feb.

PMID:
30578391
16.

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study.

de Man FM, Hussaarts KGAM, de With M, Oomen-de Hoop E, de Bruijn P, van Halteren HK, van der Burg-de Graauw NCHP, Eskens FALM, van Gelder T, van Leeuwen RWF, Mathijssen RHJ.

Clin Pharmacol Ther. 2019 Jun;105(6):1456-1461. doi: 10.1002/cpt.1331. Epub 2019 Feb 10.

17.

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11.

PMID:
30544060
18.

3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung.

Ashek A, Spruijt OA, Harms HJ, Lammertsma AA, Cupitt J, Dubois O, Wharton J, Dabral S, Pullamsetti SS, Huisman MC, Frings V, Boellaard R, de Man FS, Botros L, Jansen S, Vonk Noordegraaf A, Wilkins MR, Bogaard HJ, Zhao L.

Circ Cardiovasc Imaging. 2018 Aug;11(8):e007402. doi: 10.1161/CIRCIMAGING.117.007402.

19.

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.

Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.

PMID:
30348537
20.

Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.

Rol N, de Raaf MA, Sun XQ, Kuiper VP, da Silva Gonçalves Bos D, Happé C, Kurakula K, Dickhoff C, Thuillet R, Tu L, Guignabert C, Schalij I, Lodder K, Pan X, Herrmann FE, van Nieuw Amerongen GP, Koolwijk P, Vonk-Noordegraaf A, de Man FS, Wollin L, Goumans MJ, Szulcek R, Bogaard HJ.

Cardiovasc Res. 2019 Feb 1;115(2):432-439. doi: 10.1093/cvr/cvy186.

PMID:
30032282
21.

ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad.

Guignabert C, de Man F, Lombès M.

Eur Respir J. 2018 Jun 21;51(6). pii: 1800848. doi: 10.1183/13993003.00848-2018. Print 2018 Jun. No abstract available.

PMID:
29929959
22.

High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.

Zocca P, Kok MM, van der Heijden LC, van Houwelingen KG, Hartmann M, de Man FHAF, Stoel MG, Louwerenburg JHW, Knottnerus IL, Linssen GCM, Doggen CJM, von Birgelen C.

Int J Cardiol. 2018 Oct 1;268:11-17. doi: 10.1016/j.ijcard.2018.03.116. Epub 2018 May 23.

23.

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.

de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S.

Clin Pharmacokinet. 2018 Oct;57(10):1229-1254. doi: 10.1007/s40262-018-0644-7. Review.

24.

5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.

Zocca P, Kok MM, Tandjung K, Danse PW, Jessurun GAJ, Hautvast RWM, van Houwelingen KG, Stoel MG, Schramm AR, Tjon Joe Gin RM, de Man FHAF, Hartmann M, Louwerenburg JHW, Linssen GCM, Löwik MM, Doggen CJM, von Birgelen C.

JACC Cardiovasc Interv. 2018 Mar 12;11(5):462-469. doi: 10.1016/j.jcin.2017.11.031.

25.

"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study.

von Birgelen C, Kok MM, Sattar N, Zocca P, Doelman C, Kant GD, Löwik MM, van der Heijden LC, Sen H, van Houwelingen KG, Stoel MG, Louwerenburg JHW, Hartmann M, de Man FHAF, Linssen GCM, Doggen CJM, Tandjung K.

JACC Cardiovasc Interv. 2018 Mar 12;11(5):448-459. doi: 10.1016/j.jcin.2017.10.038. Epub 2018 Feb 14.

26.

Correction to: The Sydney Heart Bank: improving translational research while eliminating or reducing the use of animal models of human heart disease.

Dos Remedios CG, Lal SP, Li A, McNamara J, Keogh A, Macdonald PS, Cooke R, Ehler E, Knöll R, Marston SB, Stelzer J, Granzier H, Bezzina C, van Dijk S, De Man F, Stienen GJM, Odeberg J, Pontén F, Linke WA, van der Velden J.

Biophys Rev. 2018 Jun;10(3):941. doi: 10.1007/s12551-018-0397-4.

27.

Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting Stents.

van der Heijden LC, Kok MM, Zocca P, Sen H, Löwik MM, Mariani S, de Man FHAF, Hartmann M, Stoel MG, van Houwelingen KG, Louwerenburg JHW, Linssen GCM, Doggen CJM, Grandjean JG, von Birgelen C.

J Am Heart Assoc. 2018 Jan 30;7(3). pii: e007212. doi: 10.1161/JAHA.117.007212.

28.

Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.

da Silva Gonçalves Bós D, Van Der Bruggen CEE, Kurakula K, Sun XQ, Casali KR, Casali AG, Rol N, Szulcek R, Dos Remedios C, Guignabert C, Tu L, Dorfmüller P, Humbert M, Wijnker PJM, Kuster DWD, van der Velden J, Goumans MJ, Bogaard HJ, Vonk-Noordegraaf A, de Man FS, Handoko ML.

Circulation. 2018 Feb 27;137(9):910-924. doi: 10.1161/CIRCULATIONAHA.117.027451. Epub 2017 Nov 22.

PMID:
29167228
29.

Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.

Zocca P, van der Heijden LC, Kok MM, Löwik MM, Hartmann M, Stoel MG, Louwerenburg JW, de Man FHAF, Linssen GCM, Knottnerus IL, Doggen CJM, van Houwelingen KG, von Birgelen C.

EuroIntervention. 2017 Nov 20;13(10):1168-1176. doi: 10.4244/EIJ-D-17-00634.

30.

Renal Denervation Reduces Pulmonary Vascular Remodeling and Right Ventricular Diastolic Stiffness in Experimental Pulmonary Hypertension.

da Silva Gonçalves Bos D, Happé C, Schalij I, Pijacka W, Paton JFR, Guignabert C, Tu L, Thuillet R, Bogaard HJ, van Rossum AC, Vonk-Noordegraaf A, de Man FS, Handoko ML.

JACC Basic Transl Sci. 2017 Feb 1;2(1):22-35. doi: 10.1016/j.jacbts.2016.09.007. eCollection 2017 Feb.

31.

A focus on the greatness of the lesser circulation: spotlight issue on the right ventricle.

de Man FS, La Gerche A.

Cardiovasc Res. 2017 Oct 1;113(12):1421-1422. doi: 10.1093/cvr/cvx168. No abstract available.

PMID:
28957539
32.

RV pressure overload: from hypertrophy to failure.

van der Bruggen CEE, Tedford RJ, Handoko ML, van der Velden J, de Man FS.

Cardiovasc Res. 2017 Oct 1;113(12):1423-1432. doi: 10.1093/cvr/cvx145. Review.

PMID:
28957530
33.

Vascular remodelling in the pulmonary circulation after major lung resection.

Rol N, Happé C, Beliën JAM, de Man FS, Westerhof N, Vonk-Noordegraaf A, Grünberg K, Bogaard HJ.

Eur Respir J. 2017 Aug 31;50(2). pii: 1700806. doi: 10.1183/13993003.00806-2017. Print 2017 Aug. No abstract available.

34.

The Sydney Heart Bank: improving translational research while eliminating or reducing the use of animal models of human heart disease.

Dos Remedios CG, Lal SP, Li A, McNamara J, Keogh A, Macdonald PS, Cooke R, Ehler E, Knöll R, Marston SB, Stelzer J, Granzier H, Bezzina C, van Dijk S, De Man F, Stienen GJM, Odeberg J, Pontén F, Linke WA, Linke W, van der Velden J.

Biophys Rev. 2017 Aug;9(4):431-441. doi: 10.1007/s12551-017-0305-3. Epub 2017 Aug 14. Review. Erratum in: Biophys Rev. 2018 Feb 1;:. Linke W [corrected to Linke WA].

35.

Treatment response in patients with idiopathic pulmonary arterial hypertension and a severely reduced diffusion capacity.

van der Bruggen CE, Spruijt OA, Nossent EJ, Trip P, Marcus JT, de Man FS, Jan Bogaard H, Noordegraaf AV.

Pulm Circ. 2017 Mar 13;7(1):137-144. doi: 10.1086/690016. eCollection 2017 Mar.

36.

Use of β-Blockers in Pulmonary Hypertension.

Perros F, de Man FS, Bogaard HJ, Antigny F, Simonneau G, Bonnet S, Provencher S, Galiè N, Humbert M.

Circ Heart Fail. 2017 Apr;10(4). pii: e003703. doi: 10.1161/CIRCHEARTFAILURE.116.003703. Review.

PMID:
28364092
37.

Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial.

von Birgelen C, van der Heijden LC, Basalus MW, Kok MM, Sen H, Louwerenburg HW, van Houwelingen KG, Stoel MG, de Man FH, Linssen GC, Tandjung K, Doggen CJ, van der Palen J, Löwik MM.

JAMA Cardiol. 2017 Mar 1;2(3):268-276. doi: 10.1001/jamacardio.2016.5190.

PMID:
28114618
38.

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.

von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, Gin RMTJ, Somi S, van Houwelingen KG, Stoel MG, de Man FHAF, Louwerenburg JHW, Hartmann M, Zocca P, Linssen GCM, van der Palen J, Doggen CJM, Löwik MM.

Lancet. 2016 Nov 26;388(10060):2607-2617. doi: 10.1016/S0140-6736(16)31920-1. Epub 2016 Oct 30.

PMID:
27806902
39.

The effect of perioperative insulin treatment on cardiodepression in mild adiposity in mice.

Boly CA, Eringa EC, Bouwman RA, van den Akker RF, de Man FS, Schalij I, Loer SA, Boer C, van den Brom CE.

Cardiovasc Diabetol. 2016 Sep 20;15(1):135. doi: 10.1186/s12933-016-0453-y.

40.

A critical appraisal of transpulmonary and diastolic pressure gradients.

Handoko ML, De Man FS, Oosterveer FP, Bogaard HJ, Vonk-Noordegraaf A, Westerhof N.

Physiol Rep. 2016 Sep;4(17). pii: e12910. doi: 10.14814/phy2.12910.

41.

Response by van der Bruggen et al to Letter Regarding Article, "Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle".

van der Bruggen CE, Happé CM, Goumans MJ, Bogaard HJ, Vonk Noordegraaf A, de Man FS.

Circulation. 2016 Aug 30;134(9):e117-8. doi: 10.1161/CIRCULATIONAHA.116.024173. No abstract available.

PMID:
27572883
42.

Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: A patient-level pooled analysis from TWENTE and DUTCH PEERS.

Huisman J, van der Heijden LC, Kok MM, Louwerenburg JH, Danse PW, Jessurun GA, de Man FH, Löwik MM, Linssen GC, IJzerman MJ, Doggen CJ, von Birgelen C.

J Cardiol. 2017 Apr;69(4):660-665. doi: 10.1016/j.jjcc.2016.06.010. Epub 2016 Jul 28.

43.

Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure.

Bins S, Eechoute K, Kloth JS, de Man FM, Oosten AW, de Bruijn P, Sleijfer S, Mathijssen RH.

Clin Pharmacokinet. 2017 Mar;56(3):305-310. doi: 10.1007/s40262-016-0441-0.

44.

Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study.

van Campen JS, de Boer K, van de Veerdonk MC, van der Bruggen CE, Allaart CP, Raijmakers PG, Heymans MW, Marcus JT, Harms HJ, Handoko ML, de Man FS, Vonk Noordegraaf A, Bogaard HJ.

Eur Respir J. 2016 Sep;48(3):787-96. doi: 10.1183/13993003.00090-2016. Epub 2016 Jul 7.

45.

Right Ventricular Myocardial Stiffness in Experimental Pulmonary Arterial Hypertension: Relative Contribution of Fibrosis and Myofibril Stiffness.

Rain S, Andersen S, Najafi A, Gammelgaard Schultz J, da Silva Gonçalves Bós D, Handoko ML, Bogaard HJ, Vonk-Noordegraaf A, Andersen A, van der Velden J, Ottenheijm CA, de Man FS.

Circ Heart Fail. 2016 Jul;9(7). pii: e002636. doi: 10.1161/CIRCHEARTFAILURE.115.002636.

46.

Tyrosine kinase inhibitor BIBF1000 does not hamper right ventricular pressure adaptation in rats.

de Raaf MA, Herrmann FE, Schalij I, de Man FS, Vonk-Noordegraaf A, Guignabert C, Wollin L, Bogaard HJ.

Am J Physiol Heart Circ Physiol. 2016 Sep 1;311(3):H604-12. doi: 10.1152/ajpheart.00656.2015. Epub 2016 Jun 24.

47.

Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertension.

Manders E, Bonta PI, Kloek JJ, Symersky P, Bogaard HJ, Hooijman PE, Jasper JR, Malik FI, Stienen GJ, Vonk-Noordegraaf A, de Man FS, Ottenheijm CA.

Am J Physiol Lung Cell Mol Physiol. 2016 Jul 1;311(1):L20-8. doi: 10.1152/ajplung.00113.2016. Epub 2016 May 17.

48.

Pneumonectomy combined with SU5416 induces severe pulmonary hypertension in rats.

Happé CM, de Raaf MA, Rol N, Schalij I, Vonk-Noordegraaf A, Westerhof N, Voelkel NF, de Man FS, Bogaard HJ.

Am J Physiol Lung Cell Mol Physiol. 2016 Jun 1;310(11):L1088-97. doi: 10.1152/ajplung.00023.2016. Epub 2016 Apr 1.

49.

Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle.

van der Bruggen CE, Happé CM, Dorfmüller P, Trip P, Spruijt OA, Rol N, Hoevenaars FP, Houweling AC, Girerd B, Marcus JT, Mercier O, Humbert M, Handoko ML, van der Velden J, Vonk Noordegraaf A, Bogaard HJ, Goumans MJ, de Man FS.

Circulation. 2016 May 3;133(18):1747-60. doi: 10.1161/CIRCULATIONAHA.115.020696. Epub 2016 Mar 16.

PMID:
26984938
50.

Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS Trials.

Kok MM, van der Heijden LC, Sen H, Danse PW, Löwik MM, Anthonio RL, Louwerenburg JH, de Man FH, Linssen GC, IJzerman MJ, Doggen CJ, Maas AH, Mehran R, von Birgelen C.

JACC Cardiovasc Interv. 2016 Mar 28;9(6):553-61. doi: 10.1016/j.jcin.2015.10.043. Epub 2016 Mar 2.

Supplemental Content

Loading ...
Support Center